Cigna Group Q1 2026 results set the tone for margins and earnings debate

Cigna Group (CI) has just opened 2026 with its Q1 scorecard, and investors are looking at the latest revenue and EPS print alongside a trailing 12 month net profit margin of 2.2% versus 1.4% a year earlier. The company has seen total revenue move from about US$247.1b in the trailing period to Q4 2024 to US$274.9b by Q4 2025, with trailing EPS over those same periods shifting from US$12.25 to US$22.33, while quarterly revenue in 2025 ranged between US$65.5b and US$72.5b and quarterly EPS moved between US$4.67 and US$7.02. With that backdrop, Cigna is entering this results season with profitability that has edged higher on trailing figures, setting up a closer look at how durable those margins really are.

See our full analysis for Cigna Group.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the market narratives around Cigna's growth, risks, and long term margin potential, and where the latest results challenge those stories.

Revenue lifts to about US$274.9b on a trailing basis

• On a trailing 12 month view, revenue is about US$274.9b, up from US$247.1b at the end of 2024, while quarterly revenue over 2025 moved from US$65.5b in Q1 to US$72.5b in Q4.
• Consensus narrative puts a lot of weight on long term revenue stability from higher margin areas like specialty pharmacy and care services, yet the provided forecasts of about 4.6% revenue growth per year and a 2.2% net margin show a more measured pace, which sits in contrast to the larger addressable market that bulls often highlight.
  • Supportive data for the bullish view includes the rise in trailing revenue from about US$255.4b in early 2025 to US$274.9b by Q4 2025.
  • On the other hand, the modest revenue growth forecast and current 2.2% margin remind readers that even with higher margin segments, the overall business still runs on thin profitability.

TTM earnings up 73.5% while five year trend shows 11.7% annual decline

• Trailing 12 month net income is US$6.0b with a 73.5% one year earnings gain and a 2.2% net margin, compared with US$3.4b and a 1.4% margin a year earlier, yet the five year earnings trend still shows an 11.7% annual decline.
• Bulls argue that growth in Evernorth and higher margin healthcare services can support long term earnings stability, and the recent move in trailing EPS from US$12.25 to US$22.33 lines up with that, while the negative five year earnings trend and modest 3.7% forecast growth rate keep that bullish story grounded in mixed evidence.
  • The step up in trailing EPS and net income compared with the prior year backs the bullish claim that higher margin segments are contributing more to the profit pool.
  • The longer term 11.7% annual decline in earnings, along with only mid single digit forecast growth, shows that recent strength has not yet turned into a strong multi year track record.

On this set of numbers, bulls point to the TTM earnings jump and margin improvement as proof the business mix is working, while the longer term earnings decline keeps the debate alive for anyone weighing how repeatable this phase really is. 🐂 Cigna Group Bull Case

P/E of 12.9x, high debt, and large gap to DCF fair value

• Cigna trades on a trailing P/E of 12.9x, well below the cited peer average of 49.5x and US Healthcare average of 24.6x, with the stock price at US$290.58 compared with a DCF fair value of about US$891.23 and an analyst price target of about US$335.79.
• Bears highlight high debt and modest growth forecasts as reasons to question how much of that large DCF fair value gap can be realized, and the combination of 3.7% expected earnings growth, 4.6% expected revenue growth, and a 2.15% dividend yield means much of the current case rests on valuation metrics rather than rapid expansion.
  • The big spread between the current P/E of 12.9x and both peers at 49.5x and the DCF fair value near US$891.23 is central to the valuation debate that critics focus on.
  • The indicated high debt level, together with only modest mid single digit growth forecasts, underpins the cautious view that a lower P/E may be reflecting balance sheet and growth risks rather than mispricing alone.

For anyone trying to square the low P/E with the size of the DCF gap and slower forecast growth, skeptics argue the balance sheet and growth profile still matter just as much as the headline discount. 🐻 Cigna Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cigna Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both finding support in the same set of numbers, it is worth checking the details yourself and deciding where you stand. To weigh those signals side by side, take a close look at the 5 key rewards and 1 important warning sign.

See What Else Is Out There

Cigna's thin 2.2% net margin, high debt, modest 3.7% earnings and 4.6% revenue growth forecasts, and five year earnings decline leave plenty of questions for long term holders.

If those balance sheet and earnings concerns make you cautious, compare Cigna with companies screened for stronger financial footing and resilience through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.